AADI NASDAQ
Aadi Bioscience, Inc.
1W: +3.6%
1M: -13.6%
3M: -43.4%
1Y: -14.1%
3Y: -90.2%
5Y: -79.1%
$2.05
Last traded 2025-04-14 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$94.9M
52W Range1.21-3.812
Volume62,607
Avg Volume200,709
Beta0.34
Dividend—
Analyst Ratings
Company Info
CEODavid J. Lennon
Employees53
SectorHealthcare
IndustryBiotechnology
IPO Date2018-02-16
Websiteaadibio.com
17383 Sunset Boulevard
Pacific Palisades, CA 90272
US
Pacific Palisades, CA 90272
US
424 473 8055
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is actively evaluating FYARRO's efficacy in various malignancies that exhibit known mTOR pathway activation. This includes its application in 'tumor-agnostic' indications, where the focus is on specific genomic alterations that activate the mTOR pathway, irrespective of the tumor's origin. The company was established in 2007 and maintains its corporate headquarters in Pacific Palisades, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dalal Anupam | A-Award | 1,561,000 | $2.40 | 2025-03-04 |
| Castelein Caley | A-Award | 1,666,000 | $2.40 | 2025-03-04 |
| Zhao Baiteng | A-Award | 1,250,000 | $2.40 | 2025-03-04 |
| Dornan David | A-Award | 687,979 | $2.31 | 2025-03-04 |
| BALL BRYAN | A-Award | 100,000 | $2.40 | 2025-03-04 |